Another extended-release ADHD drug wins FDA nod
Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to 16 hours. Adderall XR is formulated to control symptoms in patients for up to 12 hours. Get the full story at our sister site, Drug Delivery Business News. The post Another extended-release ADHD drug wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Shire Plc. Source Type: news

Controlled-release ADHD drug wins FDA approval
Neos Therapeutics (NSDQ:NEOS) won FDA approval yesterday for its controlled-release formulation of an old ADHD drug, methylphenidate. The company touts its product, Cotempla XR-ODT, as the 1st methylphenidate tablet designed to release medication over time instead of all at once. Get the full story at our sister site, Drug Delivery Business News. The post Controlled-release ADHD drug wins FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Source Type: news

FDA Clears New Methylphenidate Formulation for ADHD FDA Clears New Methylphenidate Formulation for ADHD
Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate for patients aged 6 to 17 years with ADHD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2017 Category: Drugs & Pharmacology Source Type: news

The effects of methylphenidate on the neural signatures of sustained attention - Dockree PM, Barnes JJ, Matthews N, Dean AJ, Abe R, Nandam LS, Kelly SP, Bellgrove MA, O'Connell RG.
We examined how MPH influenced known electrophysiological precursors of lapsing attenti... (Source: SafetyLit)
Source: SafetyLit - June 14, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Ritalin LA (Methylphenidate Hydrochloride Extended-Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 9, 2017 Category: Drugs & Pharmacology Source Type: news

How Do I Keep My Prescription Stimulant Safe At College?
Discussion Going away to college presents new and exciting opportunities for young adults. It also is an important time for transitioning many adult responsibilities to the young adult too. Keeping safe is important and safety tips for college can be reviewed here. Any medication can be abused. Prescription stimulants are no different. Normally prescription stimulants are used for treatment of attention deficit disorder, narcolepsy and treatment resistant depression. They can help increase alertness, attention, and energy, cognition, learning and memory. However for these reasons and because they are easy to obtain and r...
Source: PediatricEducation.org - June 5, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Methylphenidate Hydrochloride Tablets, USP (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 17, 2017 Category: Drugs & Pharmacology Source Type: news

Nonprescription use of Ritalin linked to adverse side effects, study finds
New research has explored the potential side effects of the stimulant drug Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2017 Category: Science Source Type: news

Nonprescription use of Ritalin linked to adverse side effects, UB study finds
(University at Buffalo) New research from the University at Buffalo Research Institute on Addictions that explored the potential side effects of the stimulant drug Ritalin on those without ADHD showed changes in brain chemistry associated with risk-taking behavior, sleep disruption and other undesirable effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2017 Category: International Medicine & Public Health Source Type: news

Simulated driving skills evaluation of teenagers with attention deficit hyperactivity disorder before driving lessons - Ratzon NZ, Lunievsky EK, Ashkenasi A, Laks J, Cohen HA.
OBJECTIVE: We evaluated the driving skills of teenagers with attention deficit hyperactivity disorder (ADHD) during simulated driving before starting driving lessons and observed whether methylphenidate (MPH) affected their performance. METHOD: Six... (Source: SafetyLit)
Source: SafetyLit - April 26, 2017 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Suicide attempt with high dose long acting methylphenidate ingestion: a case presentation - Erkuran HO, Cakaloz APB, Onen O, Kutlu A.
Attention Deficit and Hyperactivity Disorder (ADHD) is among the most commonly encountered neurodevelopmental disorders in childhood with its reported worldwide prevalance as 5%. Among the recommended treatment regimens as stimulants, the most frequently a... (Source: SafetyLit)
Source: SafetyLit - April 19, 2017 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review
In conclusion, while available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimulants for ADHD core symptoms in the short term, we still need further empirical support for the non-pharmacological and multimodal treatments. A comprehensive evidence-informed hierarchy of ADHD drugs based on their efficacy and tolerability is not yet available but it should be the next research priority in the field. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater.
A recent Cochrane review assessed the efficacy of methylphenidate for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Notwithstanding the moderate-to-large effect sizes for ADHD symptom reduction found in the meta-analysis, the authors concluded that the quality of the evidence is low and therefore the true magnitude of these effects remains uncertain. We identified a number of major concerns with the review, in the domains of study inclusion, approaches to quality assessment and interpretation of data relating to serious adverse events as well as of the clinical implications of the reported ef...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news

Evidence on methylphenidate in children and adolescents with ADHD is in fact of very low quality
Banaschewski and colleagues from the European Attention Deficit Hyperactivity Disorder (ADHD) guideline group make a number of critical comments regarding our systematic review on methylphenidate for children and adolescents with ADHD. In this article, we present our views, showing that our trial selection was not flawed and was undertaken with scientific justification. Similarly, our data collection and interpretation was systematic and correct. We have followed a sound methodology for assessing risk of bias and our conclusions are not misleading. We acknowledge that different researchers might make risk of bias judgments...
Source: Current Awareness Service for Health (CASH) - March 16, 2017 Category: Consumer Health News Source Type: news